Hasil Pencarian - M Dimopoulos

  • Menampilkan 1 - 11 hasil dari 11
Perbaiki Hasil
  1. 1
    A novel microrna signature with clinical significance in multiple myeloma

    A novel microrna signature with clinical significance in multiple myeloma oleh A. Papanota, P. Artemaki, P. Karousi, C. Liacos, M. Gavriatopoulou, E. Kastritis, C. Kontos, M. Dimopoulos, A. Scorilas, E. Terpos

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY

    P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY oleh A. Oriol, M. Dimopoulos, F. Schjesvold, M. Beksac, M. Yagci, A. Larocca, S. Guo, Y. Mu, K. Hong, S. Dhanasiri, P. Richardson, K. Weisel

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Peripheral blood immune profiling of multiple myeloma patients at diagnosis: correlations with circulating plasma cells

    Peripheral blood immune profiling of multiple myeloma patients at diagnosis: correlations with circulating plasma cells oleh K. Papadimitriou, I. Ntanasis-Stathopoulos, N. Tsakirakis, M. Gavriatopoulou, I. Kostopoulos, E. Kastritis, N. Orologas-Stavrou, M. Dimopoulos, O. Tsitsilonis, E. Terpos

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY

    ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABE... oleh A. Maiolino, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study

    Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-lab... oleh M. Turgut, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL

    P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DA... oleh L. Leypoldt, M. Gavriatopoulou, B. Besemer, H. Salwender, M.-S. Raab, A. Nogai, C. Khandanpour, V. Runde, M. Zago, P. Martus, H. Goldschmidt, C. Bokemeyer, M. Dimopoulos, K. Weisel

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study

    Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study oleh E. Terpos, A. Symeonidis, S. Delimpasi, E. Zamagni, E. Katodritou, E. Rivolti, M. Kyrtsonis, D. Fotiou, N. Kanellias, M. Migkou, M. Roussou, M. Gavriatopoulou, E. Hatjiharissi, M. Cavo, M. Dimopoulos

    Diterbitkan 2020-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS

    POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK C... oleh M. Dimopoulos, K. Weisel, P. Moreau, L.D.A. Jr, D. White, J.S. Miguel, P. Sonneveld, M. Engelhardt, M. Jenner, A. Corso, J. Dürig, M. Pavic, M. Salomo, E. Casal, R. Jiang, T. Nguyen, T. Peluso, P. Richardson

    Diterbitkan 2020-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    P1159: A MULTICENTER, INTERNATIONAL COLLABORATIVE STUDY EVALUATING FRONTLINE THERAPY WITH BENDAMUSTINE RITUXIMAB FOR WALDENSTRÖM MACROGLOBULINEMIA

    P1159: A MULTICENTER, INTERNATIONAL COLLABORATIVE STUDY EVALUATING FRONTLINE THERAPY WITH BENDAMUSTINE RITUXIMAB FOR WALDENSTRÖM MACROGLOBULINEMIA oleh S. Zanwar, J. Abeykoon, J. Castillo, E. Durot, E. Kastritis, E. Uppal, P. Morel, R. Tawfiq, L. Montes, J. Paludo, S. Sarosiek, S. Kumar, O. Ogunbiyi, P. Cornillet-Lefebvre, R. Kyle, A. Delmer, M. Gertz, M. Dimopoulos, S. Ansell, S. Treon, S. D’Sa, P. Kapoor

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

    P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? oleh R Popat, A Badros, S Kumar, P Rodriguez-Otero, A Cohen, S Manier, P Voorhees, F Gay, R Rifkin, T Martin, A Chari, K Weisel, A Farooq, B Jeng, W Chng, H Lee, J Berdeja, V Jadhav, A Tosolini, L Eliason, A Palumbo, M Dimopoulos, S Lonial, S Trudel, P Richardson, E Terpos

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)

    P1161: ASPEN: LONG-TERM FOLLOW-UP RESULTS OF A PHASE 3 RANDOMIZED TRIAL OF ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR) IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) oleh M. Dimopoulos, S. Opat, S. D’Sa, W. Jurczak, H.-P. Lee, G. Cull, R. G. Owen, P. Marlton, B. E. Wahlin, R. Garcia-Sanz, H. McCarthy, S. Mulligan, A. Tedeschi, J. J. Castillo, J. Czyz, C. Fernandez De Larrea Rodriguez, D. Belada, E. Libby, J. Matous, M. Motta, T. Siddiqi, M. Tani, M. Trneny, M. Minnema, C. Buske, V. Leblond, S. P. Treon, J. Trotman, W. Y. Chan, J. Schneider, H. Allewelt, A. Cohen, J. Huang, C. S. Tam

    Diterbitkan 2022-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: